Liquid Biopsy to Identify Actionable Genomic Alterations.

Main|Search|PHGKB


Last Posted: Sep 30, 2018

---

• FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
  FDA Press Release, September 28, 2018
• Liquid Biopsy to Identify Actionable Genomic Alterations.
  Ou Sai-Hong Ignatius et al. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018 May (38) 978-997
• Next Generation Sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones - first findings from the prospective ZYSTEUS biomarker study.
  Volckmar Anna-Lena et al. Genes, chromosomes & cancer 2018 Sep
• PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.
  Alonso-Alconada L et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 May 20(5) 630-638
• Application of Liquid Biopsy in Bone and Soft Tissue Sarcomas: Present and Future.
  Li Xiaoyang et al. Cancer letters 2018 Sep
• How Blood Will Soon Tell Us Everything
  B Gates et al, Wired, September 19, 2018
• Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology.
  Palmirotta Raffaele et al. Therapeutic advances in medical oncology 2018 101758835918794630
• Liquid Biopsy 'Weather Forecast' Can Predict When Tumors Will Return
  V Forster, Forbes, August 30, 2018
• A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting.
  Sorber Laure et al. Cancers 2018 Aug 10(9)
• Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry.
  Bonaparte Eleonora et al. Diagnostic pathology 2018 Jan 13(1) 4

more